SCYNEXIS Secures Rights to PXL770 in a Deal Worth Up to $196 Million—Major Milestone for Rare Kidney Disease Pipeline
Market Chameleon (Tue, 31-Mar 11:47 AM)
SCYNEXIS Gains FDA QIDP and Fast Track Designations for SCY-247: 10 Years of Exclusivity and Accelerated Path Forward
Market Chameleon (Wed, 21-Jan 11:08 AM)
